Soekhai, Vikas http://orcid.org/0000-0003-3709-8454
Donkers, Bas
Johansson, Jennifer Viberg
Jimenez-Moreno, Cecilia
Pinto, Cathy Anne
de Wit, G. Ardine
de Bekker-Grob, Esther
Funding for this research was provided by:
Innovative Medicines Initiative (115966)
Article History
Accepted: 3 January 2023
First Online: 13 February 2023
Declarations
:
: This work was funded through the Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 115966 (this joint undertaking receives support from the European Union’s Horizon 2020 Research and Innovation programme and European Federation of Pharmaceutical Industries and Associations).
: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this manuscript. This text and its contents reflect the PREFER project’s view and not the view of IMI, the European Union, or the European Federation of Pharmaceutical Industries and Associations.
: Not available.
: Not available.
: Not available.
: The dataset is available upon request.
: The software code is available upon request.